Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT03935984

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Led by Joseph Sferra · Updated on 2024-09-19

37

Participants Needed

1

Research Sites

396 weeks

Total Duration

On this page

Sponsors

J

Joseph Sferra

Lead Sponsor

U

University of Toledo Health Science Campus

Collaborating Sponsor

AI-Summary

What this Trial Is About

Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

CONDITIONS

Official Title

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of primary hyperparathyroidism
  • Non-localizing SPECT-CT performed within 365 days prior to consent
  • Patient desires surgical treatment for primary hyperparathyroidism
  • No contraindications to 99mTC-Sestamibi
  • No contraindications to calcitonin treatment
  • Serum calcium level prior to non-localizing SPECT-CT is 610.5 mg/dL
  • Patient consents to participate and undergo second SPECT-CT for research purposes
Not Eligible

You will not qualify if you...

  • Previous neck surgery including parathyroid tissue removal, except if further surgery is medically needed
  • Contraindication to 99mTC-Sestamibi SPECT-CT due to allergy or adverse event
  • Allergy to calcitonin
  • Hypocalcemia
  • Vitamin D deficiency
  • Previous treatment with radioactive iodine
  • New thyroid medication prescription not consistent at index and research scans
  • Lithium exposure within one year of scans
  • Secondary hyperparathyroidism
  • Benign familial hypocalciuric hypercalcemia
  • Known malignancy, especially multiple endocrine neoplasia
  • New thiazide diuretic prescription not consistent at index and research scans
  • Currently taking calcium channel blockers
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

ProMedica Toledo Hospital

Toledo, Ohio, United States, 43606

Actively Recruiting

Loading map...

Research Team

L

Leah Stevenson, MS

CONTACT

D

Dawn Muskiewicz, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here